# Iteration 3 History

## User

SYSTEM: Welcome to **Iteration 3 of 3** of our *in silico* drug discovery project:

Here is the context of the project objective and scope of this iteration:

----------------------------------------------------------------------


You are now in the 'Final Lead Optimization' phase for designing an AKT1 inhibitor. You need to show your final results and make a decision.

==============================================================
FINAL LEAD OPTIMIZATION CONTEXT
--------------------------------------------------------------
1. The previous lead optimization phase ended as summarized above. We have:

   - 5 active and 5 inactive compounds (all with docking + PLIP).
   - A set of de novo molecules from the AI Expert, each with
     docking + PLIP data.
   - A target docking improvement of at least 10% over
     the best known active compound.

2. Participants:
   - Medicinal Chemist: Make modifications to the de novo molecules to increase the activity, and drug-like properties. Evaluates the new molecules with its tools. And finalizes the 10 molecules.
   - Ranking agent: Rank the molecules based on the docking scores and the other metrics.

3. Automatic Workflow:
   - Each time the Medicinal Chemist proposes a set of analogs,
     docking is run automatically, then PLIP highlights
     protein-ligand interactions.
   - The Ranking Agent see these results
     and rank them

==============================================================
RULES & FLOW
--------------------------------------------------------------
- Docking + PLIP run automatically for each analog.
- We track progress iteration by iteration, aiming to see
  if the docking surpasses the 10% improvement threshold.
- Ranking Agent should select 10 best molecules.
- Finally lets have 10 optimized molecules.
- Most important thing is for all molecules to have docking scores and other metrics.
This way ranking agent can rank them and we can see the progress.
  
==============================================================
END OF SYSTEM PROMPT


----------------------------------------------------------------------

This iteration builds upon the overall project goals and the specific directives established by the Principal Researcher at the end of the previous iteration.

**Guiding Context from Previous Iteration (Principal Researcher's Summary & Directives for this Current Iteration):
**----------------------------------------------------------------------
# Comprehensive Iteration Summary and Directives for Next Iteration LEAD OPTIMIZATION

## 1. Executive Summary of Iteration 2

In Iteration 2, our team successfully pursued two parallel optimization tracks for AKT1 inhibitors: (1) reducing lipophilicity of quinazoline scaffolds while maintaining binding affinity, and (2) enhancing binding affinity of heterocyclic scaffolds while preserving favorable physicochemical properties. We also explored a hybrid approach combining elements from both tracks. The Medicinal Chemist generated nine optimized compounds that were evaluated and ranked by the Ranking Agent, with critical scientific assessment provided by the Scientific Critic. Our efforts resulted in several promising candidates with improved profiles, particularly MC:I2:N1:G1 with exceptional binding affinity (-13.72 kcal/mol) and MC:I2:N3:G1 with an excellent balance of binding and physicochemical properties. The team successfully addressed the key objectives from Iteration 1, demonstrating that quinazoline scaffolds can be modified to reduce lipophilicity while maintaining binding, and that heterocyclic scaffolds can be optimized for enhanced binding while preserving drug-like properties.

<ranking>
{
"MC:I2:N1:G1": 1,
"MC:I2:N3:G1": 2,
"MC:I2:N5:G3": 3,
"MC:I2:N2:G2": 4,
"MC:I2:N9:G1": 5,
"MC:I2:N8:G4": 6,
"MC:I2:N4:G2": 7,
"MC:I2:N6:G2": 8,
"MC:I2:N7:G2": 9
}
</ranking>

## 2. Key In Silico Findings & Discoveries from Iteration 2

### Optimized Quinazoline Scaffolds
- **MC:I2:N1:G1** emerged as the top-ranked compound with an exceptional docking score (-13.72 kcal/mol), significantly improved logP (5.36 vs. 6.86 in parent compound DA:I1:N5:G0), and comprehensive interactions including a salt bridge with ASP292 and hydrogen bonds with SER205, THR211, ASN54, GLN79, and TRP80
- **MC:I2:N2:G2** demonstrated that further optimization of the quinazoline scaffold is possible, with a docking score of -11.82 kcal/mol and improved logP (5.02)
- **MC:I2:N9:G1** showed that truncation of the quinazoline scaffold can maintain strong binding (-11.33 kcal/mol) while significantly improving synthetic accessibility (SA: 2.64) and reducing lipophilicity (logP: 4.42)

### Enhanced Heterocyclic Scaffolds
- **MC:I2:N5:G3** achieved the best binding affinity among heterocyclic compounds (-10.89 kcal/mol) while maintaining favorable physicochemical properties (QED: 0.38, logP: 3.24)
- **MC:I2:N6:G2** demonstrated excellent drug-likeness (QED: 0.56) and very low lipophilicity (logP: 1.31) while maintaining good binding affinity (-9.31 kcal/mol)
- **MC:I2:N7:G2** achieved outstanding drug-likeness (QED: 0.63) and exceptionally low lipophilicity (logP: 0.66), though with reduced binding affinity (-8.16 kcal/mol)

### Successful Hybrid Approach
- **MC:I2:N3:G1** successfully combined elements from both tracks to create a well-balanced compound with excellent binding affinity (-11.76 kcal/mol) and significantly improved physicochemical properties (logP: 4.05) compared to original quinazoline scaffolds

### Structure-Activity Relationships
1. **Key Binding Interactions**:
   - Salt bridge with ASP292 correlates with improved binding scores in multiple compounds
   - Hydrogen bonding with SER205, THR211, ASN54, and GLN79 is critical for activity
   - π-stacking with TRP80 is maintained in all high-scoring compounds

2. **Structural Features for Optimizing Quinazoline Scaffolds**:
   - Replacement of phenyl rings with pyrimidine or pyridine effectively reduces lipophilicity while maintaining binding
   - Introduction of morpholine or piperazine substituents improves solubility and reduces logP
   - Strategic placement of polar groups (e.g., hydroxyethoxy in MC:I2:N2:G2) can reduce lipophilicity while preserving key interactions

3. **Structural Features for Enhancing Heterocyclic Scaffolds**:
   - Cyclopropyl substitution (as in MC:I2:N5:G3) can improve binding compared to linear alkyl chains
   - Methoxy substitution on pyridine rings enhances interactions with the binding site
   - Incorporation of benzimidazole moieties can improve binding while maintaining drug-like properties

4. **Hybrid Design Principles**:
   - Quinazoline binding elements can be maintained while improving drug-likeness through strategic modifications
   - Complex amine chains (as in MC:I2:N3:G1) can significantly improve physicochemical properties
   - Simplified heterocyclic cores with strategic substituents can achieve balanced profiles

## 3. In Silico Challenges & Unresolved Questions from Iteration 2

### Methodological Limitations
1. **Docking Score Reliability**:
   - Exceptionally low docking scores (< -12 kcal/mol) for several compounds may not reflect true binding potential
   - Rigid receptor assumption fails to account for protein flexibility and induced-fit effects
   - Lack of ensemble docking may overestimate binding affinities for compounds that complement the specific protein conformation used
   - Absence of validation against experimental data raises questions about the predictive value of docking scores

2. **Structure-Activity Relationship Analysis**:
   - Contribution of specific interactions (e.g., salt bridge with ASP292) to binding affinity hasn't been systematically quantified
   - Energetic contribution of individual interactions (e.g., π-stacking with TRP80) hasn't been isolated from other interactions
   - Specific contribution of each heterocycle substitution hasn't been systematically evaluated

3. **Physicochemical Property Optimization**:
   - Despite improvements, several compounds still have concerning lipophilicity (logP > 5.0)
   - QED values for quinazoline-based compounds remain low (< 0.3) despite modifications
   - Molecular weight of several compounds exceeds typical Lipinski thresholds (> 500 Da)

### Scientific Gaps
1. **Selectivity Assessment**:
   - No evaluation of potential selectivity against other AKT isoforms (AKT2, AKT3)
   - Lack of selectivity predictions against related kinases
   - Quinazoline scaffold's potential for pan-kinase inhibitory activity not addressed

2. **Metabolic Stability Considerations**:
   - Several compounds contain structural features that may be susceptible to Phase I metabolism:
     - Alkene linkers in MC:I2:N5:G3 and MC:I2:N8:G4
     - Benzimidazole moieties in MC:I2:N3:G1, MC:I2:N5:G3, and MC:I2:N8:G4
     - Hydroxyl groups in MC:I2:N2:G2 and MC:I2:N6:G2
   - No systematic assessment of metabolic stability across the compound series

3. **Pharmacophore Understanding**:
   - Formal pharmacophore model hasn't been developed to guide optimization
   - Relative importance of different structural elements for binding not fully quantified
   - Water-mediated interactions not accounted for in binding analysis

## 4. Strategic Outlook & Actionable In Silico Directives for Next Iteration

### a. Overarching Goal for Next Iteration
The primary objective for Iteration 3 is to conduct final refinement of our most promising AKT1 inhibitor candidates to produce a diverse set of 10 optimized compounds with balanced profiles of binding affinity and drug-like properties. This will involve:

1. Further optimization of the top-ranked compounds from Iteration 2 to address remaining physicochemical concerns while maintaining binding affinity
2. Systematic exploration of structural modifications to improve predicted metabolic stability and selectivity
3. Development of a more comprehensive understanding of structure-activity relationships to guide final selection
4. Finalization of a diverse set of 10 optimized compounds representing multiple structural classes with complementary strengths

### b. Specific Tasks & Focus Areas for Each Available Agent in Next Iteration

#### For Principal Researcher (Myself)
- Coordinate the final optimization efforts and ensure balanced exploration of chemical space
- Monitor progress against defined KPIs and adjust strategy as needed
- Integrate findings to develop a comprehensive understanding of structure-activity relationships
- Prepare the final analysis and selection of the 10 most promising AKT1 inhibitor candidates
- Ensure diversity in the final compound set to maximize chances of success in subsequent development stages

#### For Medicinal Chemist
1. **Refinement of Top Quinazoline Scaffolds**
   - Focus on compounds MC:I2:N1:G1 and MC:I2:N3:G1
   - Implement modifications to address remaining physicochemical concerns:
     - For MC:I2:N1:G1 (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(OCCN5CCOCC5)ccc4nc3-c3ncccn3)cc2)CC1`):
       - Reduce molecular weight by simplifying the structure while maintaining key interactions
       - Consider shortening or replacing the morpholine linker with a less complex moiety
       - Explore bioisosteric replacements for the quinazoline core to improve QED
     - For MC:I2:N3:G1 (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1N1CCN(CCN2CCOCC2)CC1`):
       - Simplify the amine chain to improve synthetic accessibility and reduce potential for off-target effects
       - Explore alternatives to the benzimidazole moiety to improve metabolic stability
   - Use VINA_REPORT tool to evaluate each modification's impact on binding and physicochemical properties
   - Target improvements in QED (> 0.4) while maintaining docking scores < -10.0 kcal/mol

2. **Optimization of Heterocyclic Scaffolds**
   - Focus on compounds MC:I2:N5:G3 and MC:I2:N6:G2
   - Implement modifications to address potential metabolic liabilities:
     - For MC:I2:N5:G3 (SMILES: `C1CC1C2=CN=C(OC)C(/C=C3\\SC(=N)NC3=O)=C2N(C)CCN1CCN(c2nc3ccccc3[nH]2)CC1`):
       - Replace the alkene linker with a more metabolically stable alternative
       - Consider alternatives to the cyclopropyl group
       - Simplify the structure to improve synthetic accessibility
     - For MC:I2:N6:G2 (SMILES: `OCCNC1=NC=C2C(=N1)N=C([C@@H](C)C3=CC=C(F)C(F)=C3)C(=O)N2CN1CCOCC1`):
       - Replace the hydroxyethyl group with a more metabolically stable alternative that maintains hydrogen bonding capability
       - Explore modifications to enhance binding affinity while maintaining excellent physicochemical properties
   - Use VINA_REPORT tool to evaluate each modification's impact on binding and physicochemical properties
   - Target improvements in docking scores (< -10.0 kcal/mol) while maintaining favorable physicochemical properties (QED > 0.5, logP < 4.0)

3. **Development of Additional Diverse Candidates**
   - Create 2-3 additional compounds based on the SAR insights from previous iterations
   - Explore structural features not fully investigated in previous iterations:
     - Alternative heterocycles as quinazoline replacements
     - Different linker types between core scaffolds and substituents
     - Novel substitution patterns on aromatic rings
   - Use VINA_REPORT tool to evaluate each compound's binding and physicochemical properties
   - Target a balance of binding affinity (docking score < -9.0 kcal/mol) and drug-likeness (QED > 0.5, logP < 5.0)

#### For Ranking Agent
- Implement a refined ranking methodology that gives appropriate weight to:
  - Docking score (25%)
  - Drug-likeness/QED (25%)
  - Lipophilicity/logP (15%)
  - Synthetic accessibility (10%)
  - Key interactions with critical residues (15%)
  - Molecular weight (5%)
  - Structural diversity (5%)
- Provide a comprehensive ranking of all compounds from Iterations 1-3
- Highlight the top 10 compounds that represent the best balance across all parameters
- Flag any compounds with extreme values in any category (e.g., logP > 6.0, MW > 550)
- Provide a brief rationale for the ranking of each compound in the top 10
- Consider potential metabolic stability in the ranking based on structural features

### c. Key Performance Indicators (KPIs) for Next Iteration

**Overall Project KPIs**
- Generation of at least 10 optimized compounds with balanced profiles
- At least 7 compounds with docking scores < -10.0 kcal/mol
- At least 5 compounds with QED > 0.4 and logP < 5.0
- At least 3 compounds with QED > 0.5 and logP < 4.0
- Maximum of 3 compounds with molecular weight > 550 Da
- Representation of at least 3 distinct structural classes in the final set
- All compounds with synthetic accessibility scores < 4.0

**Quinazoline Scaffold KPIs**
- At least 2 compounds with docking scores < -11.0 kcal/mol and logP < 5.0
- At least 1 compound with docking score < -10.0 kcal/mol and QED > 0.4
- Maintenance of key interactions with ASP292, SER205, and TRP80

**Heterocyclic Scaffold KPIs**
- At least 2 compounds with docking scores < -10.0 kcal/mol
- At least 2 compounds with QED > 0.5 and logP < 4.0
- Formation of salt bridges with ASP292 in at least 2 compounds

This comprehensive strategy will guide our team through the final optimization phase, building on the solid foundation established in Iterations 1 and 2 and addressing the identified challenges to develop a diverse set of promising AKT1 inhibitor candidates with balanced profiles of potency and drug-like properties.
----------------------------------------------------------------------

**Molecule Context:** This refers to all molecules that were generated, modified, or analyzed in the previous iteration. Key highlights include: {
   "molecules": [
      {
         "originalData": {
            "activity": "active",
            "computedProperties": {
               "dockingScore": -6.51,
               "logP": 3.72,
               "molecularWeight": 580.44,
               "plipInteractions": "Hydrophobic: LEU264, VAL270, GLN79, TRP80; Hydrogen Bond: ASP292, ASN53, ASN54, GLN79, TRP80, THR81",
               "qed": 0.29,
               "sas": 3.51
            },
            "friendlyId": "DA:I1:N1:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Known potent AKT1 inhibitor with pChEMBL value of 8.3",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "active",
            "computedProperties": {
               "dockingScore": -7.27,
               "logP": 4.4,
               "molecularWeight": 526.01,
               "plipInteractions": "Hydrophobic: VAL270, TYR272, ASP274, ASP292; Hydrogen Bond: THR211, ARG273, ASP292, CYS310, GLN79",
               "qed": 0.4,
               "sas": 3.59
            },
            "friendlyId": "DA:I1:N2:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Active AKT1 inhibitor with pChEMBL value of 6.8 and good docking score",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(/C=C/[C@@H]3CCCNC[C@H]3NC(=O)c3ccncc3)cc2)c1F.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "active",
            "computedProperties": {
               "dockingScore": -8.11,
               "logP": 4.08,
               "molecularWeight": 566.46,
               "plipInteractions": "Hydrophobic: TYR272, ARG273, ASP292, ILE84; Hydrogen Bond: THR211, TYR272, ASN54, GLN79; Pi-Stacking: TRP80",
               "qed": 0.35,
               "sas": 3.5
            },
            "friendlyId": "DA:I1:N3:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Active AKT1 inhibitor with pChEMBL value of 6.45 and excellent docking score",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(CO[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "active",
            "computedProperties": {
               "dockingScore": -8.05,
               "logP": 3.29,
               "molecularWeight": 579.46,
               "plipInteractions": "Hydrophobic: LEU210, LEU264, LYS268, TRP80; Hydrogen Bond: GLN203, LYS268, THR291, ASN54, GLN79, THR81; Halogen Bond: LYS268; Pi-Stacking: TRP80",
               "qed": 0.32,
               "sas": 3.47
            },
            "friendlyId": "DA:I1:N4:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Highly potent AKT1 inhibitor with pChEMBL value of 8.4 and excellent docking score",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(C(=O)N[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "active",
            "computedProperties": {
               "dockingScore": -12.84,
               "logP": 6.86,
               "molecularWeight": 511.63,
               "plipInteractions": "Hydrophobic: LEU210, LEU264, LYS268, VAL270, ARG273, GLN79, TRP80, ILE84; Hydrogen Bond: ASN204, SER205, ASN54, GLN79; Pi-Stacking: TYR272, TRP80; Salt Bridge: ASP292",
               "qed": 0.27,
               "sas": 2.48
            },
            "friendlyId": "DA:I1:N5:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Active AKT1 inhibitor with pChEMBL value of 6.54 and outstanding docking score",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "activity": "inactive",
            "computedProperties": {
               "dockingScore": -12.5,
               "logP": 4.68,
               "molecularWeight": 494.6,
               "plipInteractions": "Hydrophobic: VAL270, ASP292, ASN53, GLN79, TRP80; Hydrogen Bond: GLN203, SER205, ASP292, GLN79, THR82; Pi-Stacking: TRP80",
               "qed": 0.21,
               "sas": 3.13
            },
            "friendlyId": "DA:I1:N6:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive compound with pChEMBL value of 5.26 despite good docking score",
            "structure": {
               "smiles": "Cn1ccc2ccc3c4[nH]c5c(CCCN[C@H]6CC[C@H](O)CC6)cccc5c4c4c(c3c21)C(=O)NC4=O"
            }
         }
      },
      {
         "originalData": {
            "activity": "inactive",
            "computedProperties": {
               "dockingScore": -6.29,
               "logP": 3.8,
               "molecularWeight": 529.01,
               "plipInteractions": "Hydrophobic: LEU264, TYR272, ASP274, GLN79, TRP80; Hydrogen Bond: ASN54, GLN79, TRP80, THR82; Pi-Stacking: TRP80",
               "qed": 0.33,
               "sas": 3.46
            },
            "friendlyId": "DA:I1:N7:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive compound with pChEMBL value of 4.6",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(NC[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "inactive",
            "computedProperties": {
               "dockingScore": -6.63,
               "logP": 3.23,
               "molecularWeight": 529.01,
               "plipInteractions": "Hydrophobic: LEU210, VAL270, TYR272, TRP80, THR82; Hydrogen Bond: LYS179, GLN203, SER205, THR211, ASP292, GLY294, THR82",
               "qed": 0.33,
               "sas": 3.43
            },
            "friendlyId": "DA:I1:N8:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive compound with pChEMBL value of 5.52",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(CN[C@@H]3CCCNC[C@H]3NC(=O)c3ccncc3)cc2)c1F.Cl"
            }
         }
      },
      {
         "originalData": {
            "activity": "inactive",
            "computedProperties": {
               "dockingScore": -12.33,
               "logP": 7.46,
               "molecularWeight": 510.64,
               "plipInteractions": "Hydrophobic: LEU210, LEU264, LYS268, TYR272, ARG273, ILE290, ASP292, TRP80, ILE84; Hydrogen Bond: TYR326; Pi-Cation: ARG273; Pi-Stacking: TRP80",
               "qed": 0.26,
               "sas": 2.47
            },
            "friendlyId": "DA:I1:N9:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive compound with pChEMBL value of 5.5 despite good docking score",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3cc4ccccc4nc3-c3ccccc3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "activity": "inactive",
            "computedProperties": {
               "dockingScore": -12.12,
               "logP": 6.1,
               "molecularWeight": 459.58,
               "plipInteractions": "Hydrophobic: LEU210, VAL270, TYR272, ASP292, TRP80; Hydrogen Bond: SER205, TYR272, ASP274, ASN279, PHE293, THR82; Pi-Stacking: TRP80",
               "qed": 0.32,
               "sas": 2.47
            },
            "friendlyId": "DA:I1:N10:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive compound with pChEMBL value of 5.89 despite good docking score",
            "structure": {
               "smiles": "N#Cc1cnc(-c2ccc(CNCc3ccc(-c4csnn4)cc3)cc2)c(-c2ccccc2)c1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.85,
               "logP": 3.35,
               "qed": 0.77,
               "sas": 3.18
            },
            "friendlyId": "AI:I1:N1:G0",
            "rationale": "This heterocyclic compound features a pyrimidine core with a chlorophenyl substituent. It shows excellent docking score (-8.85 kcal/mol) with key interactions at ASN204, SER205, and TRP80. The molecule maintains good drug-likeness (QED: 0.77) and synthetic accessibility (SA: 3.18) while forming critical hydrogen bonds and hydrophobic interactions with the binding site.",
            "structure": {
               "smiles": "CC(C)NC1=NC=C2C(=N1)N=C([C@@H1](C)C3=CC=C(Cl)C=C3)C(=O)N2C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.72,
               "logP": 3.68,
               "qed": 0.44,
               "sas": 2.95
            },
            "friendlyId": "AI:I1:N2:G0",
            "rationale": "This triazine-based scaffold incorporates a hydroxyphenyl group similar to active AKT1 inhibitors. It forms hydrogen bonds with GLN59, GLN61, LEU78, and TRP80, which are critical residues in the binding pocket. The strong docking score (-8.72 kcal/mol) and favorable synthetic accessibility (SA: 2.95) make it a promising starting point for optimization.",
            "structure": {
               "smiles": "CC(C)C[C@@H1](CO)NC1=NC(NCC2=CC=CC=C2)=C(C3=CC=CC=C3O)N=N1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.99,
               "logP": 2.63,
               "qed": 0.82,
               "sas": 3.44
            },
            "friendlyId": "AI:I1:N3:G0",
            "rationale": "This pyridine-thiazolidinone hybrid shows excellent drug-likeness (QED: 0.82) and forms key hydrogen bonds with GLN79, THR81, and THR82. The molecule\\'s unsaturated linker provides conformational flexibility while maintaining a good docking score (-7.99 kcal/mol). The thiazolidinone ring offers hydrogen bond donor/acceptor capabilities that interact with key residues in the binding site.",
            "structure": {
               "smiles": "CCCC1=CN=CC(/C=C2\\SC(=N)NC2=O)=C1N(C)CC"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.11,
               "logP": 3.39,
               "qed": 0.56,
               "sas": 2.85
            },
            "friendlyId": "AI:I1:N4:G0",
            "rationale": "This molecule incorporates a benzimidazole moiety connected to an aminobenzamide through an unsaturated linker. It shows strong binding (docking score: -8.11 kcal/mol) with hydrogen bonds to SER205 and LEU78. The diethylamino group provides additional interactions while the benzimidazole forms \u03c0-stacking with TRP80, a key interaction observed in known AKT1 inhibitors.",
            "structure": {
               "smiles": "CCN(CC)CC1=CC=C(C(=O)NC=CC2=CC=CC3=C2NC=N3)C=C1N"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.11,
               "logP": 2.57,
               "qed": 0.46,
               "sas": 2.54
            },
            "friendlyId": "AI:I1:N5:G0",
            "rationale": "This triazole-triazine hybrid features multiple nitrogen atoms that can form hydrogen bonds with key residues. It shows excellent docking score (-8.11 kcal/mol) with hydrogen bonds to GLN203, SER205, THR211, and LYS268. The benzylamino group provides hydrophobic interactions while maintaining good synthetic accessibility (SA: 2.54). The hydroxyethyl group offers additional hydrogen bonding potential for optimization.",
            "structure": {
               "smiles": "OCCN1N=CC=C1NC2=NC3=CC(NCC4=CC=CC=C4)=CC=C3N=N2"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.68,
               "logP": 4.47,
               "qed": 0.55,
               "sas": 3.51
            },
            "friendlyId": "AI:I1:N6:G0",
            "rationale": "This polycyclic compound contains a phenol group similar to active AKT1 inhibitors. It shows strong binding (docking score: -8.68 kcal/mol) with hydrogen bonds to SER205, THR211, and ASN53. The molecule\\'s planar core enables \u03c0-stacking with TRP80 while the phenol group provides hydrogen bonding capabilities. The ethyl substituent can be modified to optimize interactions with the binding pocket.",
            "structure": {
               "smiles": "CCN1C2=C(NC3=CC=C(O)C=C3)C(=O)C=C1C=CC4=CC=CC=C42"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.0,
               "logP": 4.03,
               "qed": 0.58,
               "sas": 1.98
            },
            "friendlyId": "AI:I1:N7:G0",
            "rationale": "This molecule features multiple phenol groups that mimic the fluorophenol moiety found in active AKT1 inhibitors. It demonstrates the highest docking score (-9.0 kcal/mol) among the generated compounds and excellent synthetic accessibility (SA: 1.98). The amide linker provides hydrogen bonding capabilities while the hydroxyl groups form key interactions with SER205 and THR211. The catechol moiety offers additional hydrogen bonding potential for optimization.",
            "structure": {
               "smiles": "OC1=CC=C(C(=O)NC2=CC=CC(C3=CC=C(O)C=C3O)=C2)C=C1C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.82,
               "logP": 4.47,
               "qed": 0.53,
               "sas": 2.28
            },
            "friendlyId": "AI:I1:N8:G0",
            "rationale": "This hydrazone-based scaffold incorporates a furan ring and methoxyphenyl groups. It forms hydrogen bonds with THR211, THR291, ASP292, GLN79, and TRP80, covering key interaction points in the binding site. The molecule shows good docking score (-7.82 kcal/mol) and excellent synthetic accessibility (SA: 2.28). The methoxy groups can be modified to optimize interactions with the binding pocket.",
            "structure": {
               "smiles": "COC1=CC=CC(=C1)C(C2=CC=CO2)=NNC3=CC=C(OC)C=C3C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -6.54,
               "logP": 3.8,
               "qed": 0.45,
               "sas": 2.48
            },
            "friendlyId": "AI:I1:N9:G0",
            "rationale": "This molecule features a dihydroxyphenyl core with a flexible alkyl chain. Despite its moderate docking score (-6.54 kcal/mol), it forms important hydrogen bonds with SER205, THR211, ASP292, and TRP80. The hydroxyl groups mimic the fluorophenol moiety in known active inhibitors, while the alkyl chain provides hydrophobic interactions. The molecule\\'s high synthetic accessibility (SA: 2.48) makes it amenable to rapid optimization.",
            "structure": {
               "smiles": "CCCCCCCCOCC1=CC(O)=CC(O)=C1C(=O)COC"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.99,
               "logP": 3.41,
               "qed": 0.62,
               "sas": 3.49
            },
            "friendlyId": "AI:I1:N10:G0",
            "rationale": "This heterocyclic compound contains a hydrazone linker and a quinazoline-like scaffold. It shows good docking score (-7.99 kcal/mol) and drug-likeness (QED: 0.62). The molecule forms a hydrogen bond with THR211 and hydrophobic interactions with LEU210, LEU264, TYR272, GLN79, and TRP80. The isopropyl groups provide opportunities for optimization of hydrophobic interactions in the binding pocket.",
            "structure": {
               "smiles": "CC(C)CC=NNC(N1CC2=CC=CN=C2)=CC(C(C)C)=NC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -12.22,
               "logP": 7.13,
               "molecularWeight": 547.61,
               "plipInteractions": "Hydrogen Bond: SER205, ASN54, GLN79; Hydrophobic: LEU210, LEU264, LYS268, VAL270, ARG273, GLN79, TRP80, ILE84; Pi-Stacking: TYR272; Salt Bridge: ASP292",
               "qed": 0.25,
               "sas": 2.64
            },
            "friendlyId": "MC:I1:N1:G1",
            "parentFriendlyId": "DA:I1:N5:G0",
            "rationale": "Starting with the high-scoring DA:I1:N5:G0 (docking score -12.84), I introduced a 3,4-difluorophenyl group to replace the original phenyl substituent. This modification maintains the excellent docking score (-12.22) while introducing fluorine atoms that can form additional interactions with the binding site. The difluoro substitution pattern was chosen to improve metabolic stability by blocking potential oxidation sites. The molecule maintains key interactions with SER205, ASN54, GLN79, and forms a salt bridge with ASP292.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccc(F)c(F)c3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.44,
               "logP": 4.63,
               "molecularWeight": 355.34,
               "plipInteractions": "Hydrogen Bond: THR211, THR291, ASP274; Hydrophobic: LEU210, LEU264, TYR272, ILE290, THR82; Pi-Cation: LYS179; Pi-Stacking: TRP80; Halogen Bond: GLN203, THR291",
               "qed": 0.64,
               "sas": 2.21
            },
            "friendlyId": "MC:I1:N2:G1",
            "parentFriendlyId": "AI:I1:N7:G0",
            "rationale": "Starting with AI:I1:N7:G0 (docking score -9.0), I replaced one of the hydroxyl groups with fluorine to improve metabolic stability while maintaining hydrogen bonding capability. I also added a fluorine to the methyl group to reduce lipophilicity and block a potential metabolic site. The modified compound shows good docking score (-8.44), improved drug-likeness (QED: 0.64), and excellent synthetic accessibility (SA: 2.21). The fluorine atoms form additional halogen bonds with GLN203 and THR291, enhancing binding affinity.",
            "structure": {
               "smiles": "OC1=CC=C(C(=O)NC2=CC=CC(C3=CC=C(F)C=C3O)=C2)C=C1CF"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.71,
               "logP": 2.59,
               "molecularWeight": 426.5,
               "plipInteractions": "Hydrogen Bond: SER205, THR211; Hydrophobic: VAL270, ASN53, GLN79, TRP80; Pi-Stacking: TRP80; Salt Bridge: ASP292",
               "qed": 0.65,
               "sas": 3.38
            },
            "friendlyId": "MC:I1:N3:G1",
            "parentFriendlyId": "AI:I1:N1:G0",
            "rationale": "Starting with AI:I1:N1:G0 (docking score -8.85), I replaced the N-methyl group with a morpholinomethyl substituent to improve solubility and introduce additional hydrogen bond acceptors. This modification significantly improved the docking score from -8.85 to -9.71 kcal/mol while maintaining good drug-likeness (QED: 0.65). The morpholine group forms additional interactions with the binding site and improves the compound\\'s pharmacokinetic profile by reducing lipophilicity (logP: 2.59) compared to the parent compound.",
            "structure": {
               "smiles": "CC(C)NC1=NC=C2C(=N1)N=C([C@@H](C)C3=CC=C(F)C=C3)C(=O)N2CN1CCOCC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.44,
               "logP": 2.63,
               "molecularWeight": 440.52,
               "plipInteractions": "Hydrogen Bond: ASN204, SER205, GLN79; Hydrophobic: ASN204, LEU210, ALA212, LYS268, VAL270, ASN53, TRP80; Pi-Stacking: TRP80",
               "qed": 0.6,
               "sas": 3.3
            },
            "friendlyId": "MC:I1:N4:G2",
            "parentFriendlyId": "MC:I1:N3:G1",
            "rationale": "Building on MC:I1:N3:G1, I extended the linker between the core and the morpholine group to improve flexibility and allow the molecule to better adapt to the binding site. While the docking score slightly decreased (-9.71 to -9.44), the compound shows improved interactions with ASN204 and forms additional hydrophobic contacts with ALA212 and LYS268. The extended linker may also improve blood-brain barrier penetration if needed for CNS applications.",
            "structure": {
               "smiles": "CC(C)NC1=NC=C2C(=N1)N=C([C@@H](C)C3=CC=C(F)C=C3)C(=O)N2CCN1CCOCC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.23,
               "logP": 5.18,
               "molecularWeight": 391.32,
               "plipInteractions": "Hydrogen Bond: GLN203, LYS268, THR81, ASP292; Hydrophobic: LYS268, TYR272, ASP292, TRP80; Pi-Stacking: TRP80",
               "qed": 0.54,
               "sas": 2.17
            },
            "friendlyId": "MC:I1:N5:G2",
            "parentFriendlyId": "MC:I1:N2:G1",
            "rationale": "Starting with MC:I1:N2:G1, I replaced the fluoromethyl group with a trifluoromethyl group to enhance metabolic stability and increase binding affinity through stronger hydrophobic interactions. While the docking score slightly decreased (-8.44 to -8.23), the compound forms additional hydrogen bonds with GLN203 and LYS268. The trifluoromethyl group also serves as a bioisostere for the methyl group while being more resistant to metabolic oxidation.",
            "structure": {
               "smiles": "OC1=CC=C(C(=O)NC2=CC=CC(C3=CC=C(F)C=C3O)=C2)C=C1C(F)(F)F"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.46,
               "logP": 1.94,
               "molecularWeight": 389.53,
               "plipInteractions": "Hydrogen Bond: SER205, THR211; Hydrophobic: LEU264, VAL270, GLN79, TRP80; Pi-Stacking: TRP80; Salt Bridge: ASP292",
               "qed": 0.69,
               "sas": 3.29
            },
            "friendlyId": "MC:I1:N6:G1",
            "parentFriendlyId": "AI:I1:N3:G0",
            "rationale": "Starting with AI:I1:N3:G0 (docking score -7.99), I replaced the diethylamino group with a morpholinoethyl substituent to improve solubility and introduce additional hydrogen bond acceptors. This modification significantly improved the docking score from -7.99 to -9.46 kcal/mol while maintaining excellent drug-likeness (QED: 0.69). The morpholine group reduces lipophilicity (logP: 1.94) and improves the compound\\'s pharmacokinetic profile. The molecule forms a salt bridge with ASP292, enhancing binding affinity.",
            "structure": {
               "smiles": "CCCC1=CN=CC(/C=C2\\SC(=N)NC2=O)=C1N(C)CCN1CCOCC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.12,
               "logP": 1.86,
               "molecularWeight": 402.57,
               "plipInteractions": "Hydrogen Bond: ASN204, SER205, THR211, ASN54, GLN79; Hydrophobic: LEU264, TYR272; Pi-Stacking: TRP80; Salt Bridge: ASP292",
               "qed": 0.68,
               "sas": 3.27
            },
            "friendlyId": "MC:I1:N7:G2",
            "parentFriendlyId": "MC:I1:N6:G1",
            "rationale": "Building on MC:I1:N6:G1, I replaced the morpholine with a N-methylpiperazine to introduce a basic nitrogen that can form additional ionic interactions with acidic residues in the binding site. While the docking score slightly decreased (-9.46 to -9.12), the compound forms additional hydrogen bonds with ASN204 and ASN54. The piperazine group maintains good solubility properties while providing a handle for additional interactions. The molecule maintains excellent drug-likeness (QED: 0.68) and favorable lipophilicity (logP: 1.86).",
            "structure": {
               "smiles": "CCCC1=CN=CC(/C=C2\\SC(=N)NC2=O)=C1N(C)CCN1CCN(C)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.32,
               "logP": 4.46,
               "molecularWeight": 337.35,
               "plipInteractions": "Hydrogen Bond: ASN204, SER205, TYR272, THR291; Hydrophobic: LEU210, VAL270, TYR272, TRP80; Pi-Cation: LYS179; Pi-Stacking: TRP80",
               "qed": 0.66,
               "sas": 1.95
            },
            "friendlyId": "MC:I1:N8:G1",
            "parentFriendlyId": "AI:I1:N7:G0",
            "rationale": "Starting with AI:I1:N7:G0 (docking score -9.0), I replaced one of the catechol hydroxyl groups with fluorine to improve metabolic stability while maintaining hydrogen bonding capability. This modification slightly reduced the docking score (-9.0 to -8.32) but significantly improved drug-likeness (QED: 0.66) and maintained excellent synthetic accessibility (SA: 1.95). The compound forms additional interactions with TYR272 and maintains key \u03c0-stacking with TRP80. The fluorine substitution reduces the potential for quinone formation, a common metabolic liability of catechols.",
            "structure": {
               "smiles": "OC1=CC=C(C(=O)NC2=CC=CC(C3=CC=C(F)C=C3O)=C2)C=C1C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -13.72,
               "logP": 5.36,
               "molecularWeight": 642.76,
               "plipInteractions": "Hydrogen Bond: SER205, THR211, ASN54, GLN79, TRP80; Hydrophobic: LEU210, LEU264, LYS268, VAL270, TYR272, ASN53, GLN79, TRP80, ILE84; Pi-Stacking: TRP80; Salt Bridge: ASP292",
               "qed": 0.22,
               "sas": 3.05
            },
            "friendlyId": "MC:I2:N1:G1",
            "parentFriendlyId": "DA:I1:N5:G0",
            "rationale": "Starting with DA:I1:N5:G0, I introduced a morpholine substituent to improve solubility, replaced one phenyl ring with pyrimidine to reduce lipophilicity, and maintained the key quinazoline scaffold for binding. This modification resulted in an exceptional docking score (-13.72 kcal/mol) with multiple key interactions including a salt bridge with ASP292 and hydrogen bonds with SER205, THR211, ASN54, GLN79, and TRP80. While the logP (5.36) is still higher than ideal, it\\'s significantly improved from the parent compound (6.86).",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(OCCN5CCOCC5)ccc4nc3-c3ncccn3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -11.82,
               "logP": 5.02,
               "molecularWeight": 573.66,
               "plipInteractions": "Hydrogen Bond: ASN204, SER205, ARG273, TYR326, ASN54; Hydrophobic: VAL270, TYR272, GLN79, TRP80, ILE84; Pi-Stacking: TRP80; Pi-Cation: ARG273",
               "qed": 0.26,
               "sas": 2.91
            },
            "friendlyId": "MC:I2:N2:G2",
            "parentFriendlyId": "MC:I2:N1:G1",
            "rationale": "Building on MC:I2:N1:G1, I replaced the morpholine with a smaller, more polar hydroxyethoxy group to further improve solubility while reducing molecular weight. This modification maintained excellent binding affinity (-11.82 kcal/mol) while further reducing lipophilicity (logP: 5.02) and improving synthetic accessibility (SA: 2.91). The compound forms key interactions with ASN204, SER205, and maintains \u03c0-stacking with TRP80.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(OCCO)ccc4nc3-c3ncccn3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -11.76,
               "logP": 4.05,
               "molecularWeight": 620.8,
               "plipInteractions": "Hydrogen Bond: ASN53, GLN79; Hydrophobic: LEU210, LEU264, VAL270, TYR272, ILE290, ASP292, ASN53, GLN59, TRP80",
               "qed": 0.27,
               "sas": 3.67
            },
            "friendlyId": "MC:I2:N3:G1",
            "parentFriendlyId": "DA:I1:N5:G0",
            "rationale": "This hybrid design combines the quinazoline core from DA:I1:N5:G0 with the solubilizing groups from MC:I1:N3:G1. I simplified the structure by using a benzimidazole instead of the full quinazoline and added a piperazine-morpholine chain to improve solubility. This balanced approach resulted in excellent binding affinity (-11.76 kcal/mol) with significantly improved lipophilicity (logP: 4.05) compared to the original quinazoline scaffolds.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1N1CCN(CCN2CCOCC2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -12.01,
               "logP": 5.5,
               "molecularWeight": 564.6,
               "plipInteractions": "Hydrogen Bond: GLN203, SER205, ASN54, GLN79; Hydrophobic: LEU210, LEU264, LYS268, ARG273, GLN79, TRP80; Pi-Stacking: TYR272, TRP80; Halogen Bond: THR291",
               "qed": 0.29,
               "sas": 3.6
            },
            "friendlyId": "MC:I2:N4:G2",
            "parentFriendlyId": "MC:I1:N1:G1",
            "rationale": "Starting with MC:I1:N1:G1, I replaced one of the quinazoline phenyl rings with pyridine to reduce lipophilicity and added a hydroxyl group to the piperidine ring to improve solubility. This modification maintained excellent binding affinity (-12.01 kcal/mol) while reducing lipophilicity compared to the parent compound. The difluorophenyl group was maintained for metabolic stability and forms a halogen bond with THR291.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ncccc4nc3-c3ccc(F)c(F)c3)cc2)CC1O"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.89,
               "logP": 3.24,
               "molecularWeight": 532.67,
               "plipInteractions": "Hydrogen Bond: LEU78, TRP80; Hydrophobic: GLN59, GLN79; Pi-Stacking: TRP80",
               "qed": 0.38,
               "sas": 3.39
            },
            "friendlyId": "MC:I2:N5:G3",
            "parentFriendlyId": "MC:I1:N7:G2",
            "rationale": "Starting with MC:I1:N7:G2, I replaced the propyl group with a cyclopropyl to reduce flexibility, added a methoxy group to the pyridine ring, and incorporated a benzimidazole group to enhance binding. This modification improved the docking score from -9.12 to -10.89 kcal/mol while maintaining favorable physicochemical properties (logP: 3.24, QED: 0.38). The compound forms key hydrogen bonds with LEU78 and TRP80 and maintains \u03c0-stacking with TRP80.",
            "structure": {
               "smiles": "C1CC1C2=CN=C(OC)C(/C=C3\\SC(=N)NC3=O)=C2N(C)CCN1CCN(c2nc3ccccc3[nH]2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.31,
               "logP": 1.31,
               "molecularWeight": 446.46,
               "plipInteractions": "Hydrogen Bond: GLN203, SER205, THR211; Hydrophobic: VAL270, GLN79, TRP80; Pi-Stacking: TRP80; Salt Bridge: ASP292; Halogen Bond: TYR272",
               "qed": 0.56,
               "sas": 3.48
            },
            "friendlyId": "MC:I2:N6:G2",
            "parentFriendlyId": "MC:I1:N3:G1",
            "rationale": "Starting with MC:I1:N3:G1, I replaced the isopropyl group with a hydroxyethyl group to improve hydrogen bonding and added a second fluorine to the phenyl ring to enhance binding. This modification maintained good binding affinity (-9.31 kcal/mol) while significantly improving physicochemical properties (logP: 1.31, QED: 0.56). The compound forms a salt bridge with ASP292 and maintains key hydrogen bonds with GLN203, SER205, and THR211.",
            "structure": {
               "smiles": "OCCNC1=NC=C2C(=N1)N=C([C@@H](C)C3=CC=C(F)C(F)=C3)C(=O)N2CN1CCOCC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.16,
               "logP": 0.66,
               "molecularWeight": 424.5,
               "plipInteractions": "Hydrogen Bond: ASN204, SER205, HIS207, THR211, LEU213, TRP80; Hydrophobic: LEU264, VAL270, GLN79, TRP80; Pi-Stacking: TRP80; Salt Bridge: ASP292",
               "qed": 0.63,
               "sas": 3.58
            },
            "friendlyId": "MC:I2:N7:G2",
            "parentFriendlyId": "MC:I1:N6:G1",
            "rationale": "Starting with MC:I1:N6:G1, I replaced the alkene linker with an amide to improve stability and added a fluorine to the pyridine ring to enhance binding. This modification resulted in a slightly reduced docking score (-8.16 kcal/mol) but significantly improved physicochemical properties (logP: 0.66, QED: 0.63). The compound forms multiple hydrogen bonds with ASN204, SER205, HIS207, THR211, and LEU213, as well as a salt bridge with ASP292.",
            "structure": {
               "smiles": "CCCC1=CN=C(F)C(C(=O)N2SC(=N)NC2=O)=C1N(C)CCN1CCOCC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.65,
               "logP": 3.63,
               "molecularWeight": 546.7,
               "plipInteractions": "Hydrogen Bond: ASN204, SER205, THR211; Hydrophobic: LEU210, LEU264, VAL270, ASN53, ALA58",
               "qed": 0.35,
               "sas": 3.38
            },
            "friendlyId": "MC:I2:N8:G4",
            "parentFriendlyId": "MC:I2:N5:G3",
            "rationale": "Building on MC:I2:N5:G3, I extended the linker between the core and the piperazine group to improve flexibility and allow the molecule to better adapt to the binding site. This modification maintained excellent binding affinity (-10.65 kcal/mol) with good physicochemical properties (logP: 3.63). The compound forms key hydrogen bonds with ASN204, SER205, and THR211.",
            "structure": {
               "smiles": "C1CC1C2=CN=C(OC)C(/C=C3\\SC(=N)NC3=O)=C2N(C)CCCN1CCN(c2nc3ccccc3[nH]2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -11.33,
               "logP": 4.42,
               "molecularWeight": 535.65,
               "plipInteractions": "Hydrogen Bond: GLU17, THR82, GLU85; Hydrophobic: LYS268, TRP80, ILE84; Pi-Stacking: TRP80",
               "qed": 0.35,
               "sas": 2.64
            },
            "friendlyId": "MC:I2:N9:G1",
            "parentFriendlyId": "DA:I1:N5:G0",
            "rationale": "Starting with DA:I1:N5:G0, I truncated one of the quinazoline rings to reduce molecular weight and lipophilicity, added a piperazine group to improve solubility, and introduced a polar amide linkage. This modification maintained excellent binding affinity (-11.33 kcal/mol) while significantly improving synthetic accessibility (SA: 2.64) and reducing lipophilicity (logP: 4.42). The compound forms key hydrogen bonds with GLU17, THR82, and GLU85, and maintains \u03c0-stacking with TRP80.",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(C(=O)N3CCN(c4nc5ccccc5[nH]4)CC3)cc2)CC1"
            }
         }
      }
   ],
   "protein_data": {
      "sequence": "MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA",
      "pdb_path": "/Users/atabeyunlu/multi_agent_paper/runs_metadata/0618_1729_CRK_sonnet-3.7_3/pdb_files/4EJN.pdb"
   }
}.The Principal Researcher will now initiate this iteration's activities based on the above directives.

---

## User

```
[{'type': 'text', 'text': "Principal Researcher, the system has provided the full context for **Iteration 2**, including your 'Comprehensive Iteration Summary and Directives for Next Iteration' (which are the directives for *this current* iteration)\n\nPlease now formally commence This iteration:\n1. Remind the primary objective of this project, what protein we target, the approach etc 2. Briefly reiterate the **absolute key objectives** for this iteration that the team must focus on, drawing from your detailed directives.\n3. If necessary, provide any very brief, final clarifying remarks or points of emphasis for the specific agents based on their roles in *this* iteration's plan.\n4. Delegate to the first agent (e.g., Medicinal Chemist or Ranking Agent, as appropriate for your plan) to begin their specific tasks for This iteration."}]
```

---

## Assistant

```
[{'type': 'text', 'text': '# Commencement of Iteration 3: Final Lead Optimization for AKT1 Inhibitor Discovery\n\n## Primary Project Objective\n\nWe are conducting an *in silico* drug discovery project to identify potent and drug-like AKT1 inhibitors. AKT1 (Protein Kinase B) is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes including glucose metabolism, apoptosis, cell proliferation, and cell migration. Inhibition of AKT1 represents a promising therapeutic strategy for various diseases, particularly cancer.\n\nOur approach has been systematic and iterative:\n- Iteration 1: Initial database mining and de novo design to identify promising scaffolds\n- Iteration 2: Lead optimization focusing on two parallel tracks (quinazoline and heterocyclic scaffolds)\n- Iteration 3 (current): Final lead optimization to produce 10 optimized compounds with balanced profiles\n\n## Key Objectives for Iteration 3\n\nBased on our comprehensive analysis from Iteration 2, our absolute key objectives for this final iteration are:\n\n1. **Final Refinement of Top Candidates**: Further optimize our most promising compounds to address remaining physicochemical concerns while maintaining binding affinity.\n\n2. **Balanced Property Optimization**: Ensure our final candidates achieve a balance between potency (docking score) and drug-likeness (QED, logP, synthetic accessibility).\n\n3. **Diverse Candidate Selection**: Finalize a set of 10 optimized compounds representing multiple structural classes with complementary strengths.\n\n4. **Target Performance Metrics**:\n   - At least 7 compounds with docking scores < -10.0 kcal/mol\n   - At least 5 compounds with QED > 0.4 and logP < 5.0\n   - At least 3 compounds with QED > 0.5 and logP < 4.0\n   - All compounds with synthetic accessibility scores < 4.0\n   - Representation of at least 3 distinct structural classes\n\n5. **Docking Improvement**: Achieve at least a 10% improvement in docking score over the best known active compound.\n\n## Final Remarks for Participating Agents\n\n### For Medicinal Chemist:\n- Focus on refining our top candidates from Iteration 2, particularly MC:I2:N1:G1, MC:I2:N3:G1, MC:I2:N5:G3, and MC:I2:N6:G2\n- Address specific structural concerns identified in our previous analysis\n- Ensure all proposed molecules have complete computational data (docking scores, physicochemical properties)\n- Aim for a diverse set of final candidates that represent different structural classes and optimization strategies\n\n### For Ranking Agent:\n- Implement a balanced ranking methodology that considers multiple parameters:\n  - Docking score (25%)\n  - Drug-likeness/QED (25%)\n  - Lipophilicity/logP (15%)\n  - Synthetic accessibility (10%)\n  - Key interactions with critical residues (15%)\n  - Molecular weight (5%)\n  - Structural diversity (5%)\n- Provide clear rationales for rankings to support final candidate selection\n\n## Delegation to Begin Iteration 3\n\nI now invite the **Medicinal Chemist** to begin this final iteration by designing optimized analogs based on our most promising candidates from Iteration 2. Please focus on the specific modifications outlined in our directives, ensuring a balance between potency and drug-likeness. For each proposed molecule, please provide the SMILES structure, rationale for the modifications, and use the VINA_REPORT tool to evaluate binding affinity and physicochemical properties.'}]
```

---

## User

```
[{'type': 'text', 'text': 'Medicinal Chemist, for iteration 3/3, review the molecules presented. Propose and execute modifications to improve them, then evaluate the modified molecules using your tools. Share your work. Follow the molecule sharing format.When you are reference the SMILES and its Friendly ID when you are thinking a enhancement of a molecule.You can do multiple modifications at once to send for evaluation to the VINA_REPORT tool.'}]
```

---

## Assistant

```
[{'type': 'text', 'text': "# Medicinal Chemist: Final Lead Optimization for AKT1 Inhibitors\n\nThank you for the directive. I'll now begin the final optimization of our most promising AKT1 inhibitor candidates from Iteration 2, focusing on improving both binding affinity and drug-like properties.\n\n## Analysis of Top Candidates from Iteration 2\n\nBased on the Principal Researcher's directives, I'll focus on optimizing these key compounds:\n\n1. **MC:I2:N1:G1** (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(OCCN5CCOCC5)ccc4nc3-c3ncccn3)cc2)CC1`)\n   - Excellent docking score (-13.72 kcal/mol)\n   - High logP (5.36) and low QED (0.22)\n   - Opportunities: Reduce molecular weight, simplify structure\n\n2. **MC:I2:N3:G1** (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1N1CCN(CCN2CCOCC2)CC1`)\n   - Strong docking score (-11.76 kcal/mol)\n   - Improved logP (4.05) but still low QED (0.27)\n   - Opportunities: Simplify amine chain, improve metabolic stability\n\n3. **MC:I2:N5:G3** (SMILES: `C1CC1C2=CN=C(OC)C(/C=C3\\\\SC(=N)NC3=O)=C2N(C)CCN1CCN(c2nc3ccccc3[nH]2)CC1`)\n   - Good docking score (-10.89 kcal/mol)\n   - Favorable logP (3.24) and moderate QED (0.38)\n   - Opportunities: Replace alkene linker, optimize benzimidazole moiety\n\n4. **MC:I2:N6:G2** (SMILES: `OCCNC1=NC=C2C(=N1)N=C([C@@H](C)C3=CC=C(F)C(F)=C3)C(=O)N2CN1CCOCC1`)\n   - Moderate docking score (-9.31 kcal/mol)\n   - Excellent logP (1.31) and QED (0.56)\n   - Opportunities: Enhance binding affinity while maintaining properties\n\nLet me now design and evaluate optimized analogs for each of these compounds.\n\n## First Set of Optimizations\n\nI'll start by optimizing MC:I2:N1:G1 and MC:I2:N3:G1, focusing on reducing molecular weight and improving drug-likeness while maintaining strong binding.\n\n### Optimization of MC:I2:N1:G1\n\nFor MC:I2:N1:G1, I'll make the following modifications:\n1. Replace the morpholine with a smaller, more polar piperazine methyl group\n2. Replace one of the quinazoline rings with a smaller pyridine to reduce molecular weight\n3. Maintain the key quinazoline core for binding\n\nLet's evaluate this modification:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "### Optimization of MC:I2:N3:G1\n\nFor MC:I2:N3:G1, I'll make these modifications:\n1. Simplify the amine chain by replacing the piperazine-morpholine with a single piperazine\n2. Add a fluorine to the benzimidazole to improve metabolic stability\n3. Maintain the key quinazoline core for binding\n\nLet's evaluate this modification:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "### Optimization of MC:I2:N5:G3\n\nFor MC:I2:N5:G3, I'll make these modifications:\n1. Replace the alkene linker with a more metabolically stable amide\n2. Simplify the piperazine linker to improve synthetic accessibility\n3. Maintain the key interactions with the binding site\n\nLet's evaluate this modification:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "### Optimization of MC:I2:N6:G2\n\nFor MC:I2:N6:G2, I'll make these modifications:\n1. Replace the hydroxyethyl group with a more metabolically stable methoxyethyl group\n2. Add a nitrogen to the phenyl ring to improve binding and reduce lipophilicity\n3. Maintain the key interactions with the binding site\n\nLet's evaluate this modification:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "## Second Set of Optimizations\n\nNow I'll design additional compounds based on our top candidates, focusing on further improving drug-likeness and maintaining strong binding.\n\n### Further Optimization of MC:I2:N1:G1\n\nFor MC:I2:N1:G1, I'll make a more significant modification:\n1. Replace the quinazoline core with a smaller, more drug-like pyrimidine-based scaffold\n2. Maintain the key binding elements\n3. Reduce overall molecular weight\n\nLet's evaluate this modification:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "### Optimization of MC:I2:N9:G1\n\nFor MC:I2:N9:G1, I'll make these modifications:\n1. Replace the piperazine with a more polar morpholine-ethanol group\n2. Add a fluorine to the benzimidazole to improve metabolic stability\n3. Maintain the key quinazoline core for binding\n\nLet's evaluate this modification:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "### New Compound Based on AI:I1:N1:G0\n\nI'll design a new compound based on AI:I1:N1:G0, focusing on improving binding affinity while maintaining good drug-likeness:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "### New Compound Based on MC:I2:N7:G2\n\nI'll design a new compound based on MC:I2:N7:G2, focusing on improving binding affinity while maintaining excellent drug-likeness:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "## Third Set of Optimizations\n\nLet me design two more compounds to complete our set of 10 optimized molecules.\n\n### New Hybrid Compound Based on MC:I2:N1:G1 and MC:I2:N9:G1\n\nI'll design a hybrid compound combining elements from our top-scoring compounds:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': "### New Compound Based on MC:I2:N6:G2 with Enhanced Binding\n\nI'll design a final compound based on MC:I2:N6:G2, focusing on enhancing binding affinity:"}]
```

---

## Assistant

```
[{'type': 'text', 'text': 'Maximum iterations reached'}]
```

---

## User

```
[{'type': 'text', 'text': 'Ranking Agent, for iteration 3/3, rank the molecules discussed so far. Provide your top candidates and the ranking rationale. Follow the molecule sharing format.Always keep the format for the molecules of previous agent, DO NOT MODIFY ANY METRICS OR ID.Your role is just to rank the molecules, do not modify anything.'}]
```

---

## Assistant

```
[{'type': 'text', 'text': '# Ranking Agent: Final Molecule Ranking for AKT1 Inhibitor Project\n\n## Introduction\n\nAs the Ranking Agent, I\'ll now analyze and rank all the molecules discussed throughout our AKT1 inhibitor discovery project, with special focus on the candidates from Iterations 2 and 3. My ranking will be based on a comprehensive evaluation of multiple parameters as directed by the Principal Researcher:\n\n- Docking score (25%)\n- Drug-likeness/QED (25%)\n- Lipophilicity/logP (15%)\n- Synthetic accessibility (10%)\n- Key interactions with critical residues (15%)\n- Molecular weight (5%)\n- Structural diversity (5%)\n\n## Comprehensive Molecule Analysis\n\nLet me first analyze the key molecules from our previous iterations:\n\n### Top Molecules from Iteration 2:\n\n1. **MC:I2:N1:G1** (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(OCCN5CCOCC5)ccc4nc3-c3ncccn3)cc2)CC1`)\n   - Docking score: -13.72 kcal/mol (exceptional)\n   - LogP: 5.36 (higher than ideal but improved from parent)\n   - QED: 0.22 (poor drug-likeness)\n   - SAS: 3.05 (good synthetic accessibility)\n   - Key interactions: Salt bridge with ASP292, H-bonds with SER205, THR211, ASN54, GLN79, TRP80\n   - MW: 642.76 (high)\n\n2. **MC:I2:N3:G1** (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1N1CCN(CCN2CCOCC2)CC1`)\n   - Docking score: -11.76 kcal/mol (excellent)\n   - LogP: 4.05 (good)\n   - QED: 0.27 (poor drug-likeness)\n   - SAS: 3.67 (moderate synthetic accessibility)\n   - Key interactions: H-bonds with ASN53, GLN79; hydrophobic with multiple residues\n   - MW: 620.80 (high)\n\n3. **MC:I2:N5:G3** (SMILES: `C1CC1C2=CN=C(OC)C(/C=C3\\\\SC(=N)NC3=O)=C2N(C)CCN1CCN(c2nc3ccccc3[nH]2)CC1`)\n   - Docking score: -10.89 kcal/mol (very good)\n   - LogP: 3.24 (excellent)\n   - QED: 0.38 (moderate drug-likeness)\n   - SAS: 3.39 (good synthetic accessibility)\n   - Key interactions: H-bonds with LEU78, TRP80; π-stacking with TRP80\n   - MW: 532.67 (moderate)\n\n4. **MC:I2:N6:G2** (SMILES: `OCCNC1=NC=C2C(=N1)N=C([C@@H](C)C3=CC=C(F)C(F)=C3)C(=O)N2CN1CCOCC1`)\n   - Docking score: -9.31 kcal/mol (good)\n   - LogP: 1.31 (excellent)\n   - QED: 0.56 (good drug-likeness)\n   - SAS: 3.48 (good synthetic accessibility)\n   - Key interactions: Salt bridge with ASP292, H-bonds with GLN203, SER205, THR211\n   - MW: 446.46 (good)\n\n5. **MC:I2:N9:G1** (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(C(=O)N3CCN(c4nc5ccccc5[nH]4)CC3)cc2)CC1`)\n   - Docking score: -11.33 kcal/mol (excellent)\n   - LogP: 4.42 (moderate)\n   - QED: 0.35 (poor drug-likeness)\n   - SAS: 2.64 (excellent synthetic accessibility)\n   - Key interactions: H-bonds with GLU17, THR82, GLU85; π-stacking with TRP80\n   - MW: 535.65 (moderate)\n\n### Other Notable Molecules from Previous Iterations:\n\n6. **MC:I2:N2:G2** (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(OCCO)ccc4nc3-c3ncccn3)cc2)CC1`)\n   - Docking score: -11.82 kcal/mol (excellent)\n   - LogP: 5.02 (higher than ideal)\n   - QED: 0.26 (poor drug-likeness)\n   - SAS: 2.91 (good synthetic accessibility)\n   - Key interactions: H-bonds with ASN204, SER205, ARG273, TYR326, ASN54\n   - MW: 573.66 (high)\n\n7. **MC:I2:N7:G2** (SMILES: `CCCC1=CN=C(F)C(C(=O)N2SC(=N)NC2=O)=C1N(C)CCN1CCOCC1`)\n   - Docking score: -8.16 kcal/mol (moderate)\n   - LogP: 0.66 (excellent)\n   - QED: 0.63 (excellent drug-likeness)\n   - SAS: 3.58 (good synthetic accessibility)\n   - Key interactions: Multiple H-bonds, salt bridge with ASP292\n   - MW: 424.50 (excellent)\n\n8. **MC:I2:N8:G4** (SMILES: `C1CC1C2=CN=C(OC)C(/C=C3\\\\SC(=N)NC3=O)=C2N(C)CCCN1CCN(c2nc3ccccc3[nH]2)CC1`)\n   - Docking score: -10.65 kcal/mol (very good)\n   - LogP: 3.63 (good)\n   - QED: 0.35 (poor drug-likeness)\n   - SAS: 3.38 (good synthetic accessibility)\n   - Key interactions: H-bonds with ASN204, SER205, THR211\n   - MW: 546.70 (moderate)\n\n9. **MC:I2:N4:G2** (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ncccc4nc3-c3ccc(F)c(F)c3)cc2)CC1O`)\n   - Docking score: -12.01 kcal/mol (excellent)\n   - LogP: 5.50 (higher than ideal)\n   - QED: 0.29 (poor drug-likeness)\n   - SAS: 3.60 (moderate synthetic accessibility)\n   - Key interactions: H-bonds with GLN203, SER205, ASN54, GLN79\n   - MW: 564.60 (high)\n\n10. **DA:I1:N5:G0** (SMILES: `Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1`)\n    - Docking score: -12.84 kcal/mol (excellent)\n    - LogP: 6.86 (poor)\n    - QED: 0.27 (poor drug-likeness)\n    - SAS: 2.48 (excellent synthetic accessibility)\n    - Key interactions: Salt bridge with ASP292, H-bonds with ASN204, SER205, ASN54, GLN79\n    - MW: 511.63 (moderate)\n\n## Final Ranking of Top 10 Molecules\n\nBased on my comprehensive analysis and the weighted criteria specified by the Principal Researcher, here is my final ranking of the top 10 molecules:\n\n<ranking>\n{\n"MC:I2:N1:G1": 1,\n"MC:I2:N3:G1": 2,\n"MC:I2:N5:G3": 3,\n"MC:I2:N6:G2": 4,\n"MC:I2:N9:G1": 5,\n"MC:I2:N2:G2": 6,\n"MC:I2:N4:G2": 7,\n"MC:I2:N8:G4": 8,\n"MC:I2:N7:G2": 9,\n"DA:I1:N5:G0": 10\n}\n</ranking>\n\n## Ranking Rationale\n\n1. **MC:I2:N1:G1** (Rank 1): This molecule achieves the best overall balance of properties. Its exceptional docking score (-13.72 kcal/mol) represents a 6.9% improvement over the original DA:I1:N5:G0. While its QED is low (0.22), it shows significantly improved logP (5.36 vs 6.86) compared to the parent compound. It forms comprehensive interactions with key residues including a salt bridge with ASP292 and hydrogen bonds with SER205, THR211, ASN54, GLN79, and TRP80. The morpholine substituent improves solubility while the pyrimidine replacement reduces lipophilicity.\n\n2. **MC:I2:N3:G1** (Rank 2): This hybrid design achieves an excellent balance between binding affinity (-11.76 kcal/mol) and physicochemical properties (logP: 4.05). The simplified structure with benzimidazole instead of the full quinazoline and the addition of a piperazine-morpholine chain significantly improves solubility while maintaining strong binding. It represents a successful combination of elements from both optimization tracks.\n\n3. **MC:I2:N5:G3** (Rank 3): This heterocyclic compound achieves the best binding affinity among heterocyclic scaffolds (-10.89 kcal/mol) while maintaining favorable physicochemical properties (QED: 0.38, logP: 3.24). The cyclopropyl substitution improves binding compared to linear alkyl chains, and the methoxy substitution on the pyridine ring enhances interactions with the binding site.\n\n4. **MC:I2:N6:G2** (Rank 4): While this compound has a more moderate docking score (-9.31 kcal/mol), it demonstrates excellent drug-likeness (QED: 0.56) and very low lipophilicity (logP: 1.31). It forms a salt bridge with ASP292 and maintains key hydrogen bonds with GLN203, SER205, and THR211. This molecule represents an excellent balance of properties and would be expected to have favorable pharmacokinetics.\n\n5. **MC:I2:N9:G1** (Rank 5): This truncated quinazoline maintains excellent binding affinity (-11.33 kcal/mol) while significantly improving synthetic accessibility (SA: 2.64) and reducing lipophilicity (logP: 4.42). The introduction of a polar amide linkage and piperazine group improves solubility while maintaining key interactions with the binding site.\n\n6. **MC:I2:N2:G2** (Rank 6): This compound maintains excellent binding affinity (-11.82 kcal/mol) while reducing lipophilicity (logP: 5.02) compared to the parent compound. The replacement of the morpholine with a smaller, more polar hydroxyethoxy group improves solubility while reducing molecular weight.\n\n7. **MC:I2:N4:G2** (Rank 7): This compound demonstrates excellent binding affinity (-12.01 kcal/mol) with the replacement of one quinazoline phenyl ring with pyridine to reduce lipophilicity. The addition of a hydroxyl group to the piperidine ring improves solubility, and the difluorophenyl group is maintained for metabolic stability.\n\n8. **MC:I2:N8:G4** (Rank 8): This compound maintains excellent binding affinity (-10.65 kcal/mol) with good physicochemical properties (logP: 3.63). The extended linker between the core and the piperazine group improves flexibility and allows the molecule to better adapt to the binding site.\n\n9. **MC:I2:N7:G2** (Rank 9): While this compound has a more moderate docking score (-8.16 kcal/mol), it demonstrates outstanding drug-likeness (QED: 0.63) and exceptionally low lipophilicity (logP: 0.66). The replacement of the alkene linker with an amide improves stability, and the addition of a fluorine to the pyridine ring enhances binding.\n\n10. **DA:I1:N5:G0** (Rank 10): This original compound from the database has an excellent docking score (-12.84 kcal/mol) but poor physicochemical properties (logP: 6.86, QED: 0.27). It serves as an important reference point for our optimization efforts and demonstrates the improvements achieved through our iterative design process.\n\n## Summary of Achievements\n\nOur final set of 10 optimized compounds represents a diverse collection of structures with complementary strengths:\n\n1. **Binding Affinity**: 9 out of 10 compounds have docking scores below -9.0 kcal/mol, with 7 compounds below -10.0 kcal/mol.\n\n2. **Drug-likeness**: 5 compounds have QED values above 0.3, with 2 compounds above 0.5.\n\n3. **Lipophilicity**: 6 compounds have logP values below 5.0, with 3 compounds below 3.0.\n\n4. **Synthetic Accessibility**: All 10 compounds have synthetic accessibility scores below 4.0.\n\n5. **Structural Diversity**: The final set includes representatives from multiple structural classes:\n   - Quinazoline-based scaffolds (MC:I2:N1:G1, MC:I2:N2:G2, MC:I2:N4:G2, DA:I1:N5:G0)\n   - Hybrid designs (MC:I2:N3:G1, MC:I2:N9:G1)\n   - Heterocyclic scaffolds (MC:I2:N5:G3, MC:I2:N6:G2, MC:I2:N7:G2, MC:I2:N8:G4)\n\nOur top-ranked compound, MC:I2:N1:G1, represents a 6.9% improvement in docking score over the original active compound DA:I1:N5:G0, approaching our target of 10% improvement. More importantly, it achieves this while significantly improving physicochemical properties, particularly lipophilicity (logP reduced from 6.86 to 5.36).\n\nThis final set of compounds provides an excellent starting point for further development, with multiple candidates representing different structural classes and optimization strategies.'}]
```

